Medlinker Establishes RMB 500 Million Healthcare Industry Fund to Build a Chronic Disease Management Ecosystem

Recently, Medlinker, China’s leading chronic disease management platform, announced the official establishment of the “Hubei Zhaoyin Medlinker New Medical Industry Investment Fund” (hereinafter referred to as the Zhaoyin Medlinker New Medical Fund), with a total scale of RMB 500 million. Key partners include Changjiang Zhaoyin and Wuhan Science and Technology Investment Co., Ltd.

The newly established Medlinker New Medical Fund will primarily focus on the specialty chronic disease management sector, targeting high-quality assets in digital therapeutics, innovative out-of-hospital medical services, smart medical devices, and testing and inspection, to support the growth of more innovative healthcare enterprises.

In response, Wang Shirui, Founder and CEO of Medlinker, stated, “The Zhaoying-Medlinker New Healthcare Fund is dedicated to building an industrial closed loop that closely integrates innovative technologies with medical services, thereby constructing a technology-enabled ecosystem for chronic disease management. In the future, we will fully support outstanding entrepreneurs in the healthcare industry, truly realizing our vision of leveraging technology to help patients with chronic diseases lead high-quality lives.”

During the pandemic, relevant national government agencies issued phased and targeted policy documents to unlock the benefits of internet healthcare policies, ushering the industry into a golden period of development. This was not merely a temporary measure during the pandemic but also emphasized its role as a normalized component of the healthcare system. With the breakthrough in bottlenecks regarding online medical insurance payments, internet healthcare has entered a new window of opportunity. It is easy to foresee that numerous high-quality healthcare enterprises will emerge in the future, further perfecting the digital healthcare ecosystem.

As a rapidly emerging model, internet healthcare represents a new direction for the medical industry and facilitates supply-side reform—a key focus of China’s current healthcare system overhaul. The pandemic has spurred a surge in demand for internet healthcare, while also opening up new avenues such as online reimbursement through medical insurance. Driven by population aging and heightened health awareness among residents, the domestic market for internet-based chronic disease management boasts considerable scale and immense potential.

According to the Annual Report on China's Internet Healthcare Industry released by Analysys, driven by pandemic prevention and control demands, the market size of internet healthcare in 2020 is projected to reach RMB 200 billion, representing a year-on-year growth of 46.7%, the highest growth rate since 2015. The Blue Book on China's Internet Chronic Disease Management Industry, published by CIC Consulting, indicates that with the intensifying aging population, heightened public awareness of health management, government opening-up of online platforms for follow-up consultations, prescription issuance, and medical insurance payments, as well as the promotion of primary care family doctors, China's internet chronic disease management market will experience rapid development, with a potential market size of RMB 300 billion.

Although China’s internet-based chronic disease management market is still in its developmental stage, policies aimed at integrating the entire patient care journey are propelling the industry into an expansion phase. As a leading chronic disease management platform in China, Medlinker is committed to providing long-term, standardized chronic disease management services to a broad population of patients with chronic conditions, leveraging technology to help them achieve a high quality of life. Currently, the Medlinker platform brings together more than 800,000 real-name registered physicians and 50,000 contracted doctors across China, covering multiple chronic disease areas including cardiovascular diseases, diabetes, respiratory conditions and asthma, oncology, chronic kidney disease, liver disease, HIV, pediatrics, gynecology, general practice, traditional Chinese medicine, and mental health. The platform provides patients with a range of effective, affordable, and accessible out-of-hospital chronic disease management services—such as treatment recommendations, evaluation of therapeutic outcomes, electronic prescriptions, medication guidance, psychological counseling, and lifestyle interventions—thereby enabling effective control of their conditions.

We welcome self-nominations from high-quality targets: shenhaikun@medlinker.com